CRISPR Therapeutics to Present at the Bank of America Securities Health Care Conference
09 mai 2024 08h30 HE
|
CRISPR Therapeutics AG
ZUG, Switzerland and BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious...
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
08 mai 2024 16h00 HE
|
CRISPR Therapeutics AG
-More than 25 authorized treatment centers (ATCs) activated globally for CASGEVY™ and multiple patients have already had cells collected- -Clinical trials ongoing for next generation CAR T product...
CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing In Vivo Gene Editing Approach
08 mai 2024 07h00 HE
|
CRISPR Therapeutics AG
- ASGCT presentation demonstrates lipid nanoparticle (LNP) mediated delivery to the eye in the context of editing of the myocilin (MYOC) gene as a potential treatment for glaucoma - - Expands...
CRISPR Therapeutics to Present Oral Presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting
22 avr. 2024 16h30 HE
|
CRISPR Therapeutics AG
ZUG, Switzerland and BOSTON, April 22, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious...
CRISPR Therapeutics to Present at the Annual Needham Virtual Healthcare Conference
03 avr. 2024 08h00 HE
|
CRISPR Therapeutics AG
ZUG, Switzerland and BOSTON, April 03, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious...
CRISPR Therapeutics to Present at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting
01 avr. 2024 08h00 HE
|
CRISPR Therapeutics AG
ZUG, Switzerland and BOSTON, April 01, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious...
CRISPR Therapeutics Proposes New Appointment to the Board of Directors
13 mars 2024 08h30 HE
|
CRISPR Therapeutics AG
ZUG, Switzerland and BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious...
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
21 févr. 2024 07h30 HE
|
CRISPR Therapeutics AG
— CASGEVY™ approved in the U.S., European Union, Great Britain, the Kingdom of Saudi Arabia and Bahrain — — Clinical trials ongoing for next generation CAR T product candidates, CTX112™ and CTX131™...
CRISPR Therapeutics to Present at the Citi 2024 Virtual Oncology Leadership Summit
15 févr. 2024 08h30 HE
|
CRISPR Therapeutics AG
ZUG, Switzerland and BOSTON, Feb. 15, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious...
CRISPR Therapeutics Announces $280 Million Registered Direct Offering
13 févr. 2024 08h30 HE
|
CRISPR Therapeutics AG
- Led by new investor EcoR1 Capital and SR One with participation from existing and new investors - - Well positioned to execute on our on-going clinical trials in oncology, cardiovascular and...